Bio Path Holdings Stock Price To Sales
| BPTHDelisted Stock | USD 0.19 0.01 5.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Bio Path's long-term financial health and intrinsic value.
Bio |
Bio Path Holdings OTC Stock Price To Sales Analysis
Bio Path's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Bio Path Holdings has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Bio Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Path's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Bio Path could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics of similar companies.Bio Path is currently under evaluation in price to sales category among its peers.
Bio Fundamentals
| Return On Equity | -11.6 | ||||
| Return On Asset | -1.94 | ||||
| Current Valuation | 531.06 K | ||||
| Shares Outstanding | 5.77 M | ||||
| Shares Owned By Institutions | 7.41 % | ||||
| Number Of Shares Shorted | 79.35 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 2.33 X | ||||
| EBITDA | (15.76 M) | ||||
| Net Income | (16.08 M) | ||||
| Cash And Equivalents | 17.02 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 113 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.57 X | ||||
| Book Value Per Share | (0.19) X | ||||
| Cash Flow From Operations | (11.54 M) | ||||
| Short Ratio | 0.43 X | ||||
| Earnings Per Share | (8.34) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.05 | ||||
| Market Capitalization | 1.21 M | ||||
| Total Asset | 3.22 M | ||||
| Retained Earnings | (107.61 M) | ||||
| Working Capital | 1.14 M | ||||
| Current Asset | 9.59 M | ||||
| Current Liabilities | 937 K | ||||
| Net Asset | 3.22 M |
About Bio Path Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Path Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path Holdings based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Bio OTC Stock
If you are still planning to invest in Bio Path Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bio Path's history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |